These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 32096871)
21. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011 [TBL] [Abstract][Full Text] [Related]
22. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study. Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114 [TBL] [Abstract][Full Text] [Related]
23. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210 [TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862 [TBL] [Abstract][Full Text] [Related]
25. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer. Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140 [TBL] [Abstract][Full Text] [Related]
26. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base. Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821 [TBL] [Abstract][Full Text] [Related]
27. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G Cells; 2019 Jun; 8(6):. PubMed ID: 31197119 [TBL] [Abstract][Full Text] [Related]
28. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma. Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011 [TBL] [Abstract][Full Text] [Related]
29. Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients. Gong W; Liu Y; Seidl C; Dreyer T; Drecoll E; Kotzsch M; Bronger H; Dorn J; Magdolen V PLoS One; 2019; 14(2):e0212968. PubMed ID: 30811511 [TBL] [Abstract][Full Text] [Related]
30. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer. Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857 [TBL] [Abstract][Full Text] [Related]
31. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Hartmann LC; Lu KH; Linette GP; Cliby WA; Kalli KR; Gershenson D; Bast RC; Stec J; Iartchouk N; Smith DI; Ross JS; Hoersch S; Shridhar V; Lillie J; Kaufmann SH; Clark EA; Damokosh AI Clin Cancer Res; 2005 Mar; 11(6):2149-55. PubMed ID: 15788660 [TBL] [Abstract][Full Text] [Related]
32. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470 [TBL] [Abstract][Full Text] [Related]
34. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843 [TBL] [Abstract][Full Text] [Related]
35. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486 [TBL] [Abstract][Full Text] [Related]
36. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis. Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542 [TBL] [Abstract][Full Text] [Related]
37. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536 [TBL] [Abstract][Full Text] [Related]
38. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988 [TBL] [Abstract][Full Text] [Related]
39. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933 [TBL] [Abstract][Full Text] [Related]
40. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]